VistaGen Therapeutics (VTGN) Price & Analysis

Compare

854 Followers

VTGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.90 - $3.60

Previous CloseN/A

Volume188.19K

Average Volume (3M)584.84K

Market Cap

$102.47M

Enterprise Value$3.04M

Total Cash (Recent Filing)$63.18M

Total Debt (Recent Filing)$2.36M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 06, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding30,680,471

10 Day Avg. Volume435,202

30 Day Avg. Volume584,836

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.03

Enterprise Value/Revenue4.70

Enterprise Value/Gross Profit6.37

Enterprise Value/Ebitda-0.05

Forecast

1Y Price Target

$14.33

Price Target Upside307.10% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsA positive outcome from either study, combined with results from the prior PAL-2 study, could position the company for NDA submission.

Research And DevelopmentVistaGen continues to develop its pipeline for the pherine platform with the planned advancement of PH80 in P2 for menopause hot flashes and itruvone in major depressive disorder.

Bears Say

Timeline AdjustmentsThe company recently delayed the timeline for PALISADE-4, but the adjustment was not due to patient demand.

VistaGen Therapeutics News

Vistagen initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Vistagen (VTGN) with a Buy rating and $19 price target The company is...

2d ago

VTGN

Vistagen reports Q1 EPS (47c), consensus (44c)

Reports Q1 revenue $244,000, consensus $215,670. Cash, cash equivalents, and marketable securities were $63.2M as of June 30....

28d ago

VTGN

Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges

Vistagen Therapeutics Inc. (($VTGN)) has held its Q1 earnings call. Read on for the main highlights of the...

22d ago

VTGN

VistaGen Therapeutics: Strong Cash Position and Promising Drug Pipeline Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of...

26d ago

VTGN

Vistagen Therapeutics Reports Progress in Clinical Trials

Vistagen Therapeutics Inc. ( ($VTGN) ) has released its Q1 earnings. Here is a breakdown of the information...

27d ago

VTGN

VistaGen Reports Q1 2026 Financial Results and Update

The latest update is out from VistaGen Therapeutics ( ($VTGN) ). On August 7, 2025, Vistagen reported its...

27d ago

VTGN

Vistagen Appoints Elissa Cote as Chief Development Officer

VistaGen Therapeutics ( ($VTGN) ) has provided an announcement. On June 25, 2025, Vistagen Therapeutics announced the appointment...

2M ago

VTGN

Vistagen appoints Elissa Cote as Chief Corporate Development Officer

Vistagen (VTGN) announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Cote will...

2M ago

VTGN

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

Vistagen Therapeutics Inc. (($VTGN)) has held its Q4 earnings call. Read on for the main highlights of the...

3M ago

VTGN

Vistagen Therapeutics Reports Progress in Clinical Trials

Vistagen Therapeutics Inc. ( ($VTGN) ) has released its Q4 earnings. Here is a breakdown of the information...

3M ago

VTGN

Closing Bell Movers: Futures extend decline amid Middle East tension

In the opening hour of the evening session, the bearish turn seen in U.S. equity trading on Tuesday...

3M ago

LZB

ZTS

VistaGen Files Prospectus to Raise $175 Million

VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On June 17, 2025, Vistagen announced a prospectus supplement...

3M ago

VTGN

Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)

Reports FY25 revenue $486K vs. $1.06M last year. “This was a defining year for Vistagen (VTGN), marked by...

3M ago

VTGN

Options Volatility and Implied Earnings Moves Today, June 17, 2025

Today, several major companies are expected to report earnings: Jabil (JBL), John Wiley Sons Cl A (WLY), La-Z-Boy...

3M ago

JBL

LZB

VTGN FAQ

What was VistaGen Therapeutics’s price range in the past 12 months?

VistaGen Therapeutics lowest stock price was $1.90 and its highest was $3.60 in the past 12 months.

What is VistaGen Therapeutics’s market cap?

VistaGen Therapeutics’s market cap is $102.47M.

When is VistaGen Therapeutics’s upcoming earnings report date?

VistaGen Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 63 days.

How were VistaGen Therapeutics’s earnings last quarter?

VistaGen Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.473 by $0.003.

Is VistaGen Therapeutics overvalued?

According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does VistaGen Therapeutics pay dividends?

VistaGen Therapeutics does not currently pay dividends.

What is VistaGen Therapeutics’s EPS estimate?

VistaGen Therapeutics’s EPS estimate is -0.48.

How many shares outstanding does VistaGen Therapeutics have?

VistaGen Therapeutics has 30,680,471 shares outstanding.

What happened to VistaGen Therapeutics’s price movement after its last earnings report?

VistaGen Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.473. Following the earnings report the stock price went up 8.791%.

Which hedge fund is a major shareholder of VistaGen Therapeutics?

Currently, no hedge funds are holding shares in VTGN

VistaGen Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-46.28%

Trailing 12-Months

Asset Growth

-39.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

VistaGen Therapeutics

VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat central nervous system (CNS) disorders, with a primary emphasis on anxiety, depression, and other related conditions. The company utilizes its proprietary drug development platforms, including its stem cell technology, to create and advance new treatments that address significant unmet medical needs. VistaGen's core products include AV-101, an oral candidate for the treatment of major depressive disorder, and PH94B, a novel intranasal formulation for social anxiety disorder.

VistaGen Therapeutics (VTGN) Earnings & Revenues

Historic Earnings Reports

VTGN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant advancements in Vistagen's clinical programs and financial stability, despite increased R&D expenses and net loss. The company's progress in clinical trials and pipeline expansion is promising, although there are operational challenges such as the termination of a trial site.View all VTGN earnings summaries

VTGN Stock 12 Month Forecast

Average Price Target

$14.33

▲(307.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","20":"$20","5.75":"$5.75","10.5":"$10.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.75,10.5,15.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,4.71076923076923,5.901538461538461,7.092307692307692,8.283076923076923,9.473846153846154,10.664615384615384,11.855384615384615,13.046153846153846,14.236923076923077,15.427692307692308,16.61846153846154,17.80923076923077,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,4.351538461538461,5.183076923076923,6.014615384615384,6.846153846153847,7.677692307692308,8.509230769230768,9.340769230769231,10.172307692307692,11.003846153846155,11.835384615384616,12.666923076923077,13.498461538461537,{"y":14.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,4.172307692307692,4.8246153846153845,5.476923076923077,6.1292307692307695,6.781538461538462,7.433846153846154,8.086153846153847,8.73846153846154,9.390769230769232,10.043076923076924,10.695384615384617,11.347692307692308,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.65,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >